Cover Image
市場調查報告書

強迫性精神官能症 : 開發平台分析

Obsessive-Compulsive Disorder - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200470
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
強迫性精神官能症 : 開發平台分析 Obsessive-Compulsive Disorder - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 42 Pages
簡介

強迫性精神官能症(OCD)是抱有毫無根據的思考、恐怖(強迫觀念),並引起反覆性行動(強迫行為)這樣的特徵。主要症狀有對各種事物一直重覆同樣思考及印象──對細菌、污泥、侵入者的恐懼、暴力行為、傷愛親愛的人、不斷重覆同樣的儀式(洗手、開關門、數數、持續重覆不必要的事、重覆同樣的階段等)。主要風險要素為家族病史。主要治療法包含了抗憂鬱劑和精神藥等。

本報告提供全球各國治療強迫性精神官能症的開發中產品開發情形相關分析、產品開發與上市的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介、主要藥物概要、最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

強迫性精神官能症概要

治療藥的開發

  • 強迫性精神官能症開發中產品:概要
  • 強迫性精神官能症開發中產品:比較分析

各企業開發中的強迫性精神官能症治療藥

大學/研究機關研究中的強迫性精神官能症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確階段的產品

強迫性精神官能症治療藥:開發中的產品一覽(各企業)

強迫性精神官能症治療藥:研究中的產品一覽(大學/研究機關)

強迫性精神官能症治療藥開發企業

  • AbbVie Inc.
  • Addex Therapeutics Ltd
  • C4X Discovery Limited
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Omeros Corporation
  • Rottapharm SpA
  • Sellas Inc.

強迫性精神官能症:治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • ADX-71743
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • ADX-88178
  • bitopertin
  • CR-5542 系列
  • dipraglurant IR
  • fluvoxamine maleate
  • mavoglurant
  • Methoxycoronaridine
  • OMS-527
  • 成為中樞神經系統(CNS)疾病Orexin-1受體的拮抗劑的小分子
  • 成為中樞神經系統(CNS)疾病多巴胺轉運體(DAT)及SERT的抑制劑的小分子
  • zolpidem tartrate

強迫性精神官能症治療藥:開發中產品的最新趨勢

強迫性精神官能症治療藥:開發暫停的產品

強迫性精神官能症治療藥:開發中止的產品

強迫性精神官能症相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8280IDB

Summary

Global Markets Direct's, 'Obsessive-Compulsive Disorder - Pipeline Review, H2 2016', provides an overview of the Obsessive-Compulsive Disorder pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder
  • The report reviews pipeline therapeutics for Obsessive-Compulsive Disorder by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Obsessive-Compulsive Disorder therapeutics and enlists all their major and minor projects
  • The report assesses Obsessive-Compulsive Disorder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Obsessive-Compulsive Disorder

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Obsessive-Compulsive Disorder
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Obsessive-Compulsive Disorder Overview
  • Therapeutics Development
    • Pipeline Products for Obsessive-Compulsive Disorder - Overview
  • Obsessive-Compulsive Disorder - Therapeutics under Development by Companies
  • Obsessive-Compulsive Disorder - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Obsessive-Compulsive Disorder - Products under Development by Companies
  • Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Addex Therapeutics Ltd
    • Amorsa Therapeutics Inc.
    • C4X Discovery Holdings PLC
    • Novartis AG
    • Omeros Corporation
  • Obsessive-Compulsive Disorder - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 18-MC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-71743 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-88178 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fluvoxamine maleate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mavoglurant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-527 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target NMDA Receptor for Obsessive-Compulsive Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Obsessive-Compulsive Disorder - Dormant Projects
  • Obsessive-Compulsive Disorder - Discontinued Products
  • Obsessive-Compulsive Disorder - Product Development Milestones
    • Featured News & Press Releases
      • Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction
      • Aug 02, 2007: Jazz Pharmaceuticals, Inc. Announces Submission of Complete Responses to FDA Approvable Letters for Luvox
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Obsessive-Compulsive Disorder, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Obsessive-Compulsive Disorder - Pipeline by AbbVie Inc., H2 2016
  • Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc., H2 2016
  • Obsessive-Compulsive Disorder - Pipeline by C4X Discovery Holdings PLC, H2 2016
  • Obsessive-Compulsive Disorder - Pipeline by Novartis AG, H2 2016
  • Obsessive-Compulsive Disorder - Pipeline by Omeros Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Obsessive-Compulsive Disorder - Dormant Projects, H2 2016
  • Obsessive-Compulsive Disorder - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Obsessive-Compulsive Disorder, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top